KOSN Kosan Biosciences (MM)

HAYWARD, Calif., April 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) will announce its first quarter 2008 financial results on Thursday, May 1, 2008, after market close. The announcement of Kosan's first quarter 2008 financial results will be followed by a conference call and live webcast on May 1, 2008 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Interested parties may access the live call by dialing 888.680.0878 (US) or 617.213.4855 (international), access code 63268386. To pre-register for the call, go to https://www.theconferencingservice.com/prereg/key.process?key=PLGLKCFUP or visit the "Investors/Press" page at http://www.kosan.com/. Interested parties may listen to the webcast live at http://www.kosan.com/ by clicking on the "Webcasts" tab under the heading, "Investors/Press." The webcast is also being distributed over Thomson's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson's individual investor center at http://www.earnings.com/ or by visiting any of the investor sites in Thomson's Individual Investor Network. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents, at http://www.streetevents.com/. A telephonic replay will be available through May 8, 2008 by dialing 888-286-8010, access code: 17626068. International callers can dial 617-801-6888, access code: 17626068. About Kosan Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com/. Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc. Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc. DATASOURCE: Kosan Biosciences Incorporated CONTACT: Jane M. Green, Ph.D., VP, Corporate Communications of Kosan Biosciences Incorporated, +1-510-731-5335, mobile, +1-415-652-4819, Web site: http://www.kosan.com/

Copyright